Phlox Therapeutics pioneers gene therapy to alleviate and cure different heart diseases. The company focuses on developing innovative RNA-based therapies for cardiomyopathies.

Phlox Therapeutics

Phlox Therapeutics | 705 followers on LinkedIn. RNA&#39;s to rescue cardiomyopathies | Phlox Therapeutics pioneers gene therapy to alleviate and cure cardiomyopathies. By embracing new ideas, we want to change the world for patients to whom the current standard of care falls short by leveraging RNA-based strategies to reduce the negative effects caused by genetic mutations.

Cardiologist at University of Amsterdam, Medical Advisor at ARMGO Pharma and CMO at Phlox Therapeutics, advisor to Forbion

Yigal Pinto

Investment Manager at UvA AMC HvA Ventures Holding BV

Ross Gordon

Principal at BGV (BioGeneration Ventures)

Rianne Ellenbroek

Prof. Molecular Cardiology UMCU and Group leader, Hubrecht Institute KNAW

Eva van Rooij

We are very exited to announce that Phlox Therapeutics has secured 1.9M seed funding to drive forwards our mission to develop RNA therapies for rare genetic laminopathies. This round of funding will be instrumental in advancing the preclinical development of our lead program, bringing us one step closer to delivering life-changing treatments for patients with genetic cardiomyopathies. A hugh thank you to our investor syndicate, including ROM Utrecht Region , UvA - Amsterdam UMC - HvA Ventures Holding BV , Utrecht Holdings Seed Fund and FIRST fund , managed by BGV (BioGeneration Ventures) for their confidence and support in our vision. At Phlox, we are committed to pioneering innovative RNA-based approaches to address critical unmet needs in cardiovascular health. With this funding, we are energized to make substantial strides toward developing new treatment options that could transform the lives of those affected by cardiomyopathies. For more information, please see the press release: https://lnkd.in/dZSHEi8x

Exciting update from our CSO, Eva van Rooij ! Demonstrating the potential of gene therapy in treating cardiomyopathies, her research group's latest publication in Nature Cardiovascular Research highlights promising outcomes of PKP2 replacement in arrhythmogenic cardiomyopathy. Read more: https://lnkd.in/d-7XnWrV

Metric
Company Name	Phlox Therapeutics
Symbol
MSH ID	COM:PHLOXTHERAPEUTICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	NL
Stage
Employee Count
Website	phloxtherapeutics.com
LinkedIn	phloxtherapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

PHLO

COM:PHLOXTHERAPEUTICS

Phlox Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue